Traveling With PT-141 (Bremelanotide): What You Need to Know

HealthRX.com

Travel with Vyleesi and plan doses around the label limits

45 minutesMinimum wait before anticipated sexual activity after a doseSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 1.75 mgVyleesi dose per use, injected subcutaneously as needed into the abdomen or thighSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 8 doses per monthMonthly limit: more than 8 doses per month not recommendedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 40.0%Nausea rate on Vyleesi in pooled phase 3 trials (placebo 1.3%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 6 mmHgMaximal systolic blood pressure rise after one doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • Approved product / Vyleesi (bremelanotide) 1.75 mg subcutaneous autoinjector [1]
  • Approved use / premenopausal women with acquired, generalized HSDD [1]
  • Dosing window / at least 45 minutes before anticipated sexual activity [1]
  • 24-hour limit / no more than one dose in 24 hours [1]
  • Monthly limit / more than 8 doses per month is not recommended [1]
  • Blood pressure / maximal increase 6 mmHg systolic and 3 mmHg diastolic, usually back to baseline within 12 hours [1]
  • Common side effects / nausea 40.0%, flushing 20.3%, injection-site reactions 13.2%, headache 11.3% [1]
  • Sport status / not named on WADA's 2026 Prohibited List; S0 does not apply because it is FDA-approved [2]

Which PT-141 product is FDA-approved?

Bremelanotide is FDA-approved as Vyleesi (NDA 210557, approved June 21, 2019) for premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD [1][3]. It is a prescription-only 1.75 mg subcutaneous autoinjector [1][3]. The label says it is not indicated for men or postmenopausal women and not to enhance sexual performance [1].

PT-141 products sold as compounded or research-use peptides are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before marketing [4][1].

How does the dosing schedule work away from home?

The label directs 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity [1]. The Vyleesi label limits dosing to one dose in 24 hours and does not recommend more than 8 doses per month [1]. The label also says to stop after 8 weeks if there is no improvement in symptoms [1].

The schedule is event-based, not a daily injection [1]. The duration of effect after a dose is unknown, and the best timing window has not been fully characterized [1].

What people on Reddit report

Reddit users sharing how they timed doses, how they started low, nausea and flushing after dosing, and where their supply came from. Mostly people using it with a partner.

Deezcell · Biohacking

My advice, take it the day before or many hours before sexy time. She gets a little nauseous for a couple hours after. It's a physical reaction, not mental.

A husband reports advising timing well ahead of sex and says his wife felt mild nausea for a few hours afterward.

Read the source discussion

CuriousTech24 · Biohacking

So I would just say start low work your way up try to give yourself like a whole day and do that a couple times to figure it out.

A commenter describes a poorly timed first dose and advises a low start, building up slowly, and allowing a full day between tries.

Read the source discussion

No_name70 · erectiledysfunction

I suggest a newbie get a professional to mix and administer one's initial batch and see what dose gets the desired results and ensure it's not counterfeit or compromised.

An experienced user urges beginners to have a professional handle the first batch because of concerns about counterfeit or compromised product.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

What side effects should I expect while traveling?

In the pooled phase 3 trials, nausea occurred in 40.0% of Vyleesi patients versus 1.3% on placebo; flushing in 20.3% versus 0.3%; injection-site reactions in 13.2% versus 8.4%; headache in 11.3% versus 1.9%; and vomiting in 4.8% versus 0.2% [1]. Serious adverse reactions occurred in 1.1% versus 0.5%, and 18% versus 2% stopped treatment because of adverse reactions [1].

Nausea had a median onset within one hour and lasted about two hours [1]. It was highest after the first dose, reported in 21% of patients, then fell to about 3% after later doses; 13% used anti-nausea medicine and 8% stopped the trials because of nausea [1]. Pretreatment with oral ondansetron 8 mg 30 minutes before a single 1.75 mg dose did not reduce nausea in a phase 4 study of 228 healthy women and is not recommended [1].

Focal hyperpigmentation was reported by 1% of patients who received up to 8 doses per month, compared with none on placebo [1]. In another study, 38% developed focal hyperpigmentation after daily dosing for 8 days, and an additional 14% after 8 more consecutive days; risk is higher in darker skin and with daily dosing, and resolution was not confirmed in all patients [1].

What are the blood-pressure precautions?

Each dose transiently increases blood pressure and reduces heart rate [1]. In clinical studies, the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart-rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. In an ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart-rate decrease of 0.5 beats per minute [1].

Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1]. The label says it is not recommended in patients at high risk for cardiovascular disease and says to assess cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment [1].

Which drug interactions matter?

Vyleesi may slow gastric emptying and reduce absorption of oral medicines [1]. The label says to avoid it with oral drugs that depend on threshold blood levels, such as antibiotics, and to consider skipping it if a quick effect from an oral medicine such as indomethacin is wanted [1]. In clinical pharmacology studies, only naltrexone and indomethacin were meaningfully affected [1].

The Vyleesi label says to avoid combining it with oral naltrexone used for alcohol or opioid addiction because reduced naltrexone exposure could lead to treatment failure [1]. In a crossover study of 24 healthy volunteers, alcohol 0.6 g/kg did not change bremelanotide blood levels, and flushing and headache rates were similar to the higher of the two single-agent rates; that study used a 20 mg intranasal dose, about 2.5-fold the Cmax of Vyleesi [1].

What does the label say about pregnancy?

The label says to stop Vyleesi if pregnancy is suspected and to use effective contraception [1]. In animals, fetal harm occurred in dogs at exposures at least 16 times the human dose by AUC, and this label section is being revised by the October 22, 2026 supplement [1][5].

What about sport and competition?

Bremelanotide is not named on WADA's 2026 Prohibited List [2]. Because it is approved by FDA, WADA's S0 class, which covers substances with no approval from any governmental health authority, does not cover it by definition [2].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. How long before anticipated sexual activity does the label direct a Vyleesi dose to be given?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Does travel change the dosing schedule?
No. The label recommends 1.75 mg subcutaneously as needed at least 45 minutes before sexual activity, no more than one dose in 24 hours, and says that more than 8 doses per month is not recommended [1].
Can I drink alcohol with Vyleesi?
In a 24-volunteer crossover study, alcohol 0.6 g/kg did not change bremelanotide blood levels; flushing and headache were similar to the higher single-agent rate. The study used a 20 mg intranasal dose, about 2.5-fold the Cmax of Vyleesi [1].
Is compounded PT-141 the same as Vyleesi?
No. Vyleesi is the FDA-approved bremelanotide product; compounded or research-use PT-141 is not Vyleesi and is not FDA-approved [1][4].
Can I use bremelanotide in sport competition?
It is not named on WADA's 2026 Prohibited List, and S0 does not apply because it is FDA-approved [2].
Show all 8 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. World Anti-Doping Agency. 2026 Prohibited List
  3. U.S. Food and Drug Administration.
  4. Official web page.
  5. U.S. Food and Drug Administration.
  6. Reddit participants. Does PT-141 increase the libido? (r/Biohacking). Accessed 2026-11-11.
  7. Reddit participants. PT-141 Experience - it absolutely works (r/erectiledysfunction). Accessed 2026-11-11.
  8. Reddit participants. PT-141 deep dive: the libido peptide that works on your brain, not your blood flow (r/NTNPerformance). Accessed 2026-11-11.
PT-141 travel: evidence summary chart
Image: HealthRX.com. Full PT-141 travel guide and sources at healthrx.com/lifestyle-pt-141.